アブストラクト
| Title | RSウイルス感染症の治療 |
|---|---|
| Subtitle | 総説 |
| Authors | 橋本浩一 |
| Authors (kana) | |
| Organization | 福島県立医科大学医学部小児科学講座 |
| Journal | 日本小児呼吸器学会雑誌 |
| Volume | 31 |
| Number | 1 |
| Page | 41-47 |
| Year/Month | 2020 / |
| Article | 報告 |
| Publisher | 日本小児呼吸器学会 |
| Abstract | 要旨: RSV感染症はその疾病負担にも関わらず, いまだに有効な治療法は確立されていない. RSV感染による重症下気道炎の治療は対症, 支持療法が主であり特異的な治療法は研究段階である. 感染後の気道中のウイルス量, 臨床経過, さらに抗ウイルス薬の成人での臨床試験の結果から, 感染初期の投薬開始が重要であることが示唆される. 抗ウイルス剤, 単クローナル抗体, ワクチンの臨床試験が進行中であり, RSV感染症の診療に新たな方向性が見出されると思われる. |
| Practice | 臨床医学：内科系 |
| Keywords | RSウイルス, 治療, 特異的治療, 抗RSV薬, Palivizumab |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Lozano R, Naghavi M, Foreman K, et al: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
- 2) Kim HW, Arrobio JO, Brandt CD, et al: Epidemiology of respiratory syncytial virus in Washington, DC. I. Importance of the virus in different respiratory tract diseases syndromes and temporal distribution of infection. Am J Epidemiol 1973; 98: 216-225.
- 3) Law BJ, Wang EE, MacDonald N, et al: Does ribavirin impact on the hospital course of children with respiratory syncytial virus(RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada(PICNIC) RSV database. Pediatrics 1997; 99: E7.
- 4) Brooks AM, McBride JT, McConnochie KM, et al: Predicting deterioration in previously healthy infants hospitalized with respiratory syncytial virus infection. Pediatrics 1999; 104: 463-467.
- 5) Boyce TG, Mellen BG, Mitchel EF Jr, et al: Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000; 137: 865-870.
残りの15件を表示する
- 6) Karron RA, Wright PF, Crowe JE Jr, et al: Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 1997; 176: 1428-1436.
- 7) Takeyama A, Hashimoto K, Sato M, et al: Respiratory syncytial virus shedding by children hospitalized with lower respiratory tract infection. J Med Virol 2016; 88: 938-946.
- 8) Caballero MT, Polack FP, Stein RT: Viral bronchiolitis in young infants: new perspectives for management and treatment. J Pediatr(Rio J) 2017; 93 Suppl 1: 75-83.
- 9) Jorquera PA, Tripp RA: Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Rev Respir Med 2017; 11: 609-615.
- 10) Shah JN, Chemaly RF: Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117: 2755-2763.
- 11) Hirsch HH, Martino R, Ward KN, et al: Fourth European Conference on Infections in Leukaemia(ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56: 258-266.
- 12) Law BJ, Wang EE, MacDonald N, et al: Does ribavirin impact on the hospital course of children with respiratory syncytial virus(RSV) infection? An analysis using the pediatric investigators collaborative network on infections in Canada(PICNIC) RSV database. Pediatrics 1997; 99: E7.
- 13) DeVincenzo JP, Whitley RJ, Mackman RL, et al: Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014; 371: 711-722.
- 14) DeVincenzo JP, McClure MW, Symons JA, et al: Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 2015; 373: 2048-2058.
- 15) Andabaka T, Nickerson JW, Rojas-Reyes MX, et al: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013; 30: CD006602.
- 16) Malley R, DeVincenzo J, Ramilo O, et al: Reduction of respiratory syncytial virus(RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998; 178: 1555-1561.
- 17) Graham BS, Modjarrad K, McLellan JS: Novel antigens for RSV vaccines. Curr Opin Immunol 2015; 35: 30-38.
- 18) McLellan JS, Chen M, Leung S, et al: Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013; 340: 1113-1117.
- 19) Griffin MP, Khan AA, Esser MT, et al: Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-Targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother 2017; 61: e01714-16.
- 20) Mazur NI, Higgins D, Nunes MC, et al: The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis 2018; 18: e295-e311.
